Amgen (AMGN) Q2 2024 earnings summary

Executive summary

• Q2 2024 revenues rose 20% year-over-year to $8.4 billion, driven by 26% volume growth, strong double-digit sales in 12 products, and significant contributions from the Horizon acquisition.

• Net income for Q2 2024 was $746 million, down 46% year-over-year, reflecting higher operating expenses and amortization from acquired assets.

• Major pipeline progress included FDA approvals for IMDELLTRA and BLINCYTO, and positive Phase 3 data for UPLIZNA.

• Internal innovation investment reached $1.4 billion in Q2, up 30% year-over-year, and the dividend increased 6% year-over-year to $2.25 per share.

• Integration of the Horizon acquisition is progressing, contributing to revenue, pipeline expansion, and targeted $500 million in pretax synergies by year three.

Financial highlights

• Q2 2024 total revenue was $8.4 billion, up 20% year-over-year, with product sales at $8.04 billion and 26% volume growth.

• Non-GAAP operating margin was 48.2% of product sales; non-GAAP operating expenses rose 30% year-over-year.

• Free cash flow was $2.2 billion, down from $3.8 billion last year due to timing of tax payments.

• Dividend per share increased 6% year-over-year to $2.25.

• Debt reduced by $1.4 billion in Q2 and $2.0 billion year-to-date; cash and investments at $9.3 billion, debt at $62.6 billion as of June 30, 2024.

Outlook and guidance

• 2024 total revenue guidance: $32.8 billion–$33.8 billion; non-GAAP EPS: $19.10–$20.10; GAAP EPS: $6.57–$7.62.

• Full-year non-GAAP R&D expenses to increase over 25% year-over-year, reflecting investment in late-stage pipeline.

• CapEx guidance raised to ~$1.3 billion for 2024 to support manufacturing expansion.

• Non-GAAP operating margin for 2024 expected to be roughly 47% of product sales.

• Share repurchases capped at $500 million for 2024; on track to retire over $10 billion in debt by end of 2025.